Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $2,894 - $3,236
-50 Reduced 0.94%
5,290 $307,000
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $25,484 - $28,295
-400 Reduced 6.97%
5,340 $341,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $44,377 - $51,982
-750 Reduced 11.56%
5,740 $340,000
Q2 2021

Aug 13, 2021

SELL
$61.91 - $67.42 $1,114 - $1,213
-18 Reduced 0.28%
6,490 $434,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $52,812 - $59,398
-890 Reduced 12.03%
6,508 $411,000
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $24,120 - $26,728
-420 Reduced 5.37%
7,398 $446,000
Q4 2019

Feb 13, 2020

SELL
$49.21 - $64.19 $23,227 - $30,297
-472 Reduced 5.69%
7,818 $502,000
Q2 2019

Aug 13, 2019

SELL
$44.62 - $49.34 $6,693 - $7,401
-150 Reduced 1.78%
8,290 $376,000
Q1 2019

May 14, 2019

SELL
$45.12 - $53.8 $10,828 - $12,912
-240 Reduced 2.76%
8,440 $403,000
Q4 2018

Feb 12, 2019

SELL
$48.76 - $63.23 $53,636 - $69,553
-1,100 Reduced 11.25%
8,680 $451,000
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $33,114 - $37,350
-600 Reduced 5.78%
9,780 $607,000
Q2 2018

Aug 08, 2018

SELL
$50.53 - $62.98 $5,053 - $6,298
-100 Reduced 0.95%
10,380 $574,000
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $296,604 - $341,451
-4,950 Reduced 32.08%
10,480 $663,000
Q4 2017

Feb 12, 2018

SELL
$59.94 - $65.35 $46,153 - $50,319
-770 Reduced 4.75%
15,430 $946,000
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $894,726 - $1.03 Million
16,200
16,200 $1.03 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Overbrook Management Corp Portfolio

Follow Overbrook Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Overbrook Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Overbrook Management Corp with notifications on news.